According to The New York Times, artificial intelligence was used to help develop rentosertib, a drug candidate designed to treat a rare lung condition. The drug’s maker now claims that rentosertib also appears to reduce the biological hallmarks of aging, based on early data.
The development represents an emerging application of AI in pharmaceutical research, where machine learning algorithms can help identify promising drug candidates more rapidly than traditional methods. While rentosertib was initially developed for a specific rare lung condition, the company’s preliminary findings suggest broader potential effects on age-related biological markers.
The New York Times reports that these are early-stage results, and the extent of the anti-aging effects and their clinical significance remain to be fully established through further research and trials. The use of AI in drug discovery has accelerated in recent years, with companies increasingly turning to computational methods to identify therapeutic compounds that might have been overlooked through conventional screening processes.